))
Bringing PRRT to First Line: NETTER-2
Manage episode 446696643 series 3585940
Content provided by JNM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by JNM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients.
Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/
10 episodes
Share
